Vaccine

Scorpius Holdings Appoints New VP of Business Development Shari Udoff-McDonald

Biopharma industry veteran joins Scorpius’ leadership teamDURHAM, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX)…

1 month ago

PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024

PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage…

1 month ago

Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc.…

1 month ago

Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference

PRINCETON, NJ / ACCESSWIRE / May 6, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a biopharmaceutical company developing innovative targeted…

2 months ago

Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates

Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)Prepares for…

2 months ago

PDS Biotech Appoints Stephan Toutain as Chief Operating Officer

Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)PRINCETON, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB)…

2 months ago

Provectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia)

KNOXVILLE, TN, May 02, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that…

2 months ago

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June…

2 months ago

Pancreatic Cancer: Successful Trial Against Pancreatic Cancer with Defence Therapeutics’ ARM-002 Anti-Cancer Vaccine

Vancouver, British Columbia--(Newsfile Corp. - May 1, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or…

2 months ago

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon

SHELTON, CT / ACCESSWIRE / April 30, 2024 / NanoViricides, Inc. (NYSE Amer:NNVC) (the "Company"), a global leader in broad-spectrum…

2 months ago